annual cash & cash equivalents:
$5.52B-$7.29B(-56.89%)Summary
- As of today (May 29, 2025), ABBV annual cash & cash equivalents is $5.52 billion, with the most recent change of -$7.29 billion (-56.89%) on December 31, 2024.
- During the last 3 years, ABBV annual cash & cash equivalents has fallen by -$4.22 billion (-43.32%).
- ABBV annual cash & cash equivalents is now -86.16% below its all-time high of $39.92 billion, reached on December 31, 2019.
Performance
ABBV Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$5.17B-$349.00M(-6.32%)Summary
- As of today (May 29, 2025), ABBV quarterly cash & cash equivalents is $5.17 billion, with the most recent change of -$349.00 million (-6.32%) on March 1, 2025.
- Over the past year, ABBV quarterly cash & cash equivalents has dropped by -$12.89 billion (-71.36%).
- ABBV quarterly cash & cash equivalents is now -87.42% below its all-time high of $41.14 billion, reached on March 31, 2020.
Performance
ABBV quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ABBV Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -56.9% | -71.4% |
| 3 y3 years | -43.3% | -15.1% |
| 5 y5 years | -86.2% | -87.4% |
ABBV Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -56.9% | at low | -71.4% | at low |
| 5 y | 5-year | -86.2% | at low | -87.4% | at low |
| alltime | all time | -86.2% | >+9999.0% | -87.4% | >+9999.0% |
ABBV Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $5.17B(-6.3%) |
| Dec 2024 | $5.52B(-56.9%) | $5.52B(-23.9%) |
| Sep 2024 | - | $7.26B(-44.7%) |
| Jun 2024 | - | $13.13B(-27.3%) |
| Mar 2024 | - | $18.07B(+41.0%) |
| Dec 2023 | $12.81B(+39.3%) | $12.81B(-3.6%) |
| Sep 2023 | - | $13.29B(+51.7%) |
| Jun 2023 | - | $8.76B(+30.5%) |
| Mar 2023 | - | $6.71B(-27.1%) |
| Dec 2022 | $9.20B(-5.6%) | $9.20B(-22.2%) |
| Sep 2022 | - | $11.83B(+38.9%) |
| Jun 2022 | - | $8.52B(+39.7%) |
| Mar 2022 | - | $6.10B(-37.4%) |
| Dec 2021 | $9.75B(+15.4%) | $9.75B(-20.0%) |
| Sep 2021 | - | $12.18B(+42.5%) |
| Jun 2021 | - | $8.55B(-12.4%) |
| Mar 2021 | - | $9.76B(+15.5%) |
| Dec 2020 | $8.45B(-78.8%) | $8.45B(+7.1%) |
| Sep 2020 | - | $7.89B(+31.1%) |
| Jun 2020 | - | $6.02B(-85.4%) |
| Mar 2020 | - | $41.14B(+3.1%) |
| Dec 2019 | $39.92B(+447.7%) | $39.92B(+274.9%) |
| Sep 2019 | - | $10.65B(+105.9%) |
| Jun 2019 | - | $5.17B(+5.6%) |
| Mar 2019 | - | $4.90B(-32.8%) |
| Dec 2018 | $7.29B | $7.29B(-9.1%) |
| Sep 2018 | - | $8.02B(+126.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2018 | - | $3.55B(-60.6%) |
| Mar 2018 | - | $9.01B(-3.2%) |
| Dec 2017 | $9.30B(+82.4%) | $9.30B(+10.1%) |
| Sep 2017 | - | $8.45B(+38.7%) |
| Jun 2017 | - | $6.09B(+28.4%) |
| Mar 2017 | - | $4.74B(-7.1%) |
| Dec 2016 | $5.10B(-39.3%) | $5.10B(-18.0%) |
| Sep 2016 | - | $6.22B(-1.7%) |
| Jun 2016 | - | $6.33B(-16.3%) |
| Mar 2016 | - | $7.56B(-10.0%) |
| Dec 2015 | $8.40B(+0.6%) | $8.40B(-8.9%) |
| Sep 2015 | - | $9.22B(+24.6%) |
| Jun 2015 | - | $7.40B(-6.4%) |
| Mar 2015 | - | $7.91B(-5.3%) |
| Dec 2014 | $8.35B(-13.0%) | $8.35B(+8.1%) |
| Sep 2014 | - | $7.72B(-15.0%) |
| Jun 2014 | - | $9.09B(+11.6%) |
| Mar 2014 | - | $8.14B(-15.2%) |
| Dec 2013 | $9.60B(+62.6%) | $9.60B(+6.9%) |
| Sep 2013 | - | $8.97B(+2.7%) |
| Jun 2013 | - | $8.74B(+25.3%) |
| Mar 2013 | - | $6.98B(+18.3%) |
| Dec 2012 | $5.90B(>+9900.0%) | $5.90B(+113.7%) |
| Sep 2012 | - | $2.76B(+3604.2%) |
| Jun 2012 | - | $74.54M(+81.8%) |
| Mar 2012 | - | $41.00M(+51.8%) |
| Dec 2011 | $27.00M(+180.0%) | $27.00M |
| Dec 2010 | $9.64M | - |
FAQ
- What is AbbVie annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for AbbVie?
- What is AbbVie annual cash & cash equivalents year-on-year change?
- What is AbbVie quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for AbbVie?
- What is AbbVie quarterly cash & cash equivalents year-on-year change?
What is AbbVie annual cash & cash equivalents?
The current annual cash & cash equivalents of ABBV is $5.52B
What is the all time high annual cash & cash equivalents for AbbVie?
AbbVie all-time high annual cash & cash equivalents is $39.92B
What is AbbVie annual cash & cash equivalents year-on-year change?
Over the past year, ABBV annual cash & cash equivalents has changed by -$7.29B (-56.89%)
What is AbbVie quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of ABBV is $5.17B
What is the all time high quarterly cash & cash equivalents for AbbVie?
AbbVie all-time high quarterly cash & cash equivalents is $41.14B
What is AbbVie quarterly cash & cash equivalents year-on-year change?
Over the past year, ABBV quarterly cash & cash equivalents has changed by -$12.89B (-71.36%)